Bessemer Group Inc. Has $25.25 Million Stock Position in Dr. Reddy’s Laboratories Ltd $RDY

Bessemer Group Inc. lifted its holdings in shares of Dr. Reddy’s Laboratories Ltd (NYSE:RDY) by 28.4% during the 1st quarter, HoldingsChannel.com reports. The firm owned 1,823,285 shares of the company’s stock after buying an additional 403,219 shares during the period. Bessemer Group Inc.’s holdings in Dr. Reddy’s Laboratories were worth $25,253,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Aikya Investment Management Ltd increased its position in Dr. Reddy’s Laboratories by 9.3% during the fourth quarter. Aikya Investment Management Ltd now owns 7,338,525 shares of the company’s stock worth $103,033,000 after buying an additional 623,518 shares during the last quarter. B. Metzler seel. Sohn & Co. AG raised its holdings in Dr. Reddy’s Laboratories by 912.6% during the fourth quarter. B. Metzler seel. Sohn & Co. AG now owns 344,786 shares of the company’s stock valued at $4,841,000 after buying an additional 310,737 shares in the last quarter. Arta Finance Wealth Management LLC acquired a new stake in shares of Dr. Reddy’s Laboratories in the fourth quarter worth about $626,000. Frank Rimerman Advisors LLC lifted its position in shares of Dr. Reddy’s Laboratories by 185.8% in the first quarter. Frank Rimerman Advisors LLC now owns 174,383 shares of the company’s stock worth $2,415,000 after buying an additional 113,367 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. boosted its stake in shares of Dr. Reddy’s Laboratories by 0.5% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 13,154,524 shares of the company’s stock worth $184,690,000 after acquiring an additional 70,018 shares in the last quarter. Institutional investors own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Stock Performance

NYSE:RDY opened at $12.63 on Friday. The firm has a market capitalization of $10.55 billion, a PE ratio of 21.78, a PEG ratio of 1.90 and a beta of 0.25. Dr. Reddy’s Laboratories Ltd has a 1 year low of $12.19 and a 1 year high of $15.67. The company has a current ratio of 1.80, a quick ratio of 1.34 and a debt-to-equity ratio of 0.03. The firm’s fifty day simple moving average is $13.61 and its 200 day simple moving average is $13.70.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Dr. Reddy’s Laboratories had a return on equity of 12.34% and a net margin of 12.90%.The firm had revenue of $852.55 million for the quarter, compared to analyst estimates of $886.58 million. On average, sell-side analysts anticipate that Dr. Reddy’s Laboratories Ltd will post 0.52 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on RDY. The Goldman Sachs Group downgraded Dr. Reddy’s Laboratories from a “neutral” rating to a “sell” rating in a research note on Thursday, April 23rd. Weiss Ratings cut Dr. Reddy’s Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, June 11th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce”.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Ltd. is an India‐based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company’s core activities include the development and commercialization of cost‐effective generic treatments for branded drugs that have lost patent protection, along with in‐house research into innovative molecule development.